Nieuws en video's - APTORUM GROUP LTD.

Aptorum Group Limited (Nasdaq : APM, Euronext Paris : APM) (« Aptorum Group » ou la « Société »), a annoncé aujourd'hui avoir conclu une lettre d'intention non contraignante et une liste de conditions (« Term Sheet ») pour l'acquisition (« Transaction ») de la totalité de URF Holding Group Limited et de ses entreprises sous-jacentes (collectivement « U Group ») par une nouvelle émission d'actions ordinaires de classe A de la Société en contrepartie. La stratégie commerciale d'U...

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that it entered into a non-binding Letter of Intent and Term Sheet (“Term Sheet”) for the acquisition (“Transaction”) of 100% of URF Holding Group Limited and its underlying businesses (collectively “U Group”) by the further issuance of the Company’s class A ordinary shares as consideration. U Group’s business strategy, based on the urban...

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the completion of an end of Phase 1 (EOP1) meeting with the US Food and Drug Administration (“US FDA”). SACT-1 is a repurposed small molecule drug formulated in oral suspension targeting neuroblastoma in pediatric patients and has also received orphan drug designation previously from the US FDA. The EOP1 meeting was focused on...

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions with the US Food and Drug Administration (“US FDA”). ALS-4 is a first-in-class small molecule anti-virulence drug targeting infections caused by Staphylococcus aureus, including but not limited to Methicillin Resistant Staphylococcus Aureus (“MRSA”). Upon the completion of...

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to tackling unmet medical needs, announces the exciting commercial launch of NativusWell ® , a new dietary supplement supporting women’s health throughout the Menopausal cycles targeting the China market. NativusWell ® has commenced collaboration with one of the largest e-commerce platforms in China,...

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold a special extraordinary meeting of shareholders at the London office 4T.07, 17 Hanover Square, Mayfair London, England W1S 1BN at 10:00 a.m. London Time on February 21, 2023 (5:00 a.m. Eastern Standard Time on...

Aptorum Group Limited (Nasdaq:APM) (“ Aptorum Group ”), een biofarmaceutisch bedrijf dat zich toelegt op de ontwikkeling van nieuwe therapieën voor onvervulde medische behoeften wereldwijd, kondigde vandaag aan dat de Franse regelgevende instantie Autorité des Marchés Financiers (“ AMF ”) zijn prospectus goedkeuring nr. 20-352 heeft verleend voor een snelle secundaire notering van zijn gewone aandelen klasse A (de “ Aandelen ”) in het Professional Compartment van Euronext in...

Aptorum Group Limited (Nasdaq : APM) (« Aptorum Group »), société pharmaceutique axée sur le développement de nouveaux produits thérapeutiques visant à répondre à des besoins médicaux encore non satisfaits dans le monde, est heureuse d’annoncer aujourd’hui que l’Autorité des Marchés Financiers (« AMF ») a apposé le visa n° 20-352 sur son prospectus pour la cotation, dans le cadre d’une procédure de Fast Path , de ses actions ordinaires de catégorie A (les « Actions...

Aptorum Group Limited (Nasdaq:APM) (“ Aptorum Group ”), una società farmaceutica che sviluppa terapie innovative per far fronte a esigenze mediche non soddisfatte globali, è lieta di annunciare che l’autorità di controllo dei mercati finanziari francesi Autorité des Marchés Financiers (“ AMF ”) ha approvato il suo prospetto informativo, numero di visto 20-352, riguardo al cross listing con percorso veloce delle sue azioni ordinarie di Classe A (le “ Azioni ”) sul Professional...

Aptorum Group Limited (Nasdaq:APM) (" Aptorum Group "), una compañía biofarmacéutica centrada en el desarrollo de nuevas terapias para hacer frente a las necesidades médicas mundiales no satisfechas, se complace en anunciar que la Autorité des Marchés Financiers ("AMF") de Francia ha concedido el visado número 20-352 en su prospecto con respecto a su cotización cruzada de vía rápida de sus acciones ordinarias de clase A (las " Acciones ") en el segmento profesional de Euronext en...

Regulatory News: Aptorum Group Limited (Nasdaq:APM) (“ Aptorum Group ”), a biopharmaceutical company focusing on the development of novel therapeutics to address global unmet medical needs, today is pleased to announce that the French Autorité des Marchés Financiers (“ AMF ”) has granted visa number 20-352 on its prospectus in respect of its fast path cross-listing of its Class A Ordinary Shares (the “ Shares ”) on the Professional Compartment of Euronext in Paris. The Company did...

Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the appointment of Dr. Kira Sheinerman as the senior strategic consultant based in New York effective immediately. “We are really excited to welcome Dr. Sheinerman to the team,” said Mr. Ian Huen, CEO and Executive Director of Aptorum Group. “Dr. Sheinerman has comprehensive professional experience in the life sciences and...

Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced an interview with its President, Darren Lui, will air on The RedChip Money Report television program. The interview will air Sunday, May 31, at 3 p.m. local time on Bloomberg International, available in 100+ million homes across Europe. In the exclusive interview, Lui provides an overview of the Company’s development pipeline...

Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced President and Executive Director Darren Lui will share insight into the company’s recent developments and upcoming milestones during an investor webinar on Tuesday, May 19, 2020 at 4:00 p.m. ET. A live Q&A session with Lui will follow the presentation. To participate in the webinar, please register at...

Aptorum Group Limited (Nasdaq:APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, including orphan diseases, infectious diseases and metabolic diseases, today announced its participation at Maxim Group’s Infectious Disease Virtual Conference on May 5, 2020, 10:00 a.m. ET. Aptorum Group’s President and Executive Director Mr. Darren Lui will join a panel, which entitled “Non-antibiotic...

Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced financial results for the fiscal year ended December 31, 2019, and provided a business update. Aptorum Group’s operational plans remain on track. In particular, the recently announced updates on SACT-1 (targeting neuroblastoma) and ALS-4 (targeting Staphylococcus aureus ) remain on track for its pre-IND preparation work. The...

NEW YORK, NY / ACCESSWIRE / April 15, 2020 / Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, including orphan diseases, infectious diseases and metabolic diseases today announced that it will be presenting at the Planet MicroCap Showcase 2020 on Wednesday, April 22 at 8:40 AM EST. Executive Director and President of Aptorum Group, Mr. Darren Lui, will be hosting the...

Aptorum Group Limited (Nasdaq: APM) ('Aptorum Group'), een biofarmaceutisch bedrijf dat zich richt op de ontwikkeling van nieuwe therapieën voor onvervulde behoeften, inclusief maar niet beperkt tot infectieziekten, wees- en stofwisselingsziekten, heeft vandaag aangekondigd dat het een aanvullend onderzoeks- en ontwikkelingsproject start gericht op de coronavirusgroep en de eerste screening heeft voltooid onder het Smart-ACT™ -platform, een platform voor de ontdekking van herontwikkelde en...

Aptorum Group colabora con Covar Pharmaceuticals en la investigación de al menos 3 candidatos a fármacos reutilizados (SACT-COV19) para la enfermedad de coronavirus 2019 (COVID-19) en el marco de la plataforma Smart-ACT ™ y la plataforma Acticule de enfermedades infecciosas existentes Aptorum Group Limited (Nasdaq: APM) (en adelante, "Aptorum Group"), una compañía biofarmacéutica dedicada al desarrollo de terapias novedosas para necesidades no satisfechas, incluidas, entre otras, áreas...

Le Groupe Aptorum collabore avec Covar Pharmaceuticals pour étudier au moins 3 candidats-médicaments reconvertis (SACT-COV19) pour le traitement du Coronavirus 2019 (COVID-19) via ses plateformes existantes Smart-AC ™ et Articule, dédiée aux maladies infectieuses Aptorum Group Limited (Nasdaq: APM) ("Le Groupe Aptorum"), une société biopharmaceutique axée sur la création de nouveaux traitements destinés à répondre à des besoins médicaux non satisfaits, y compris, mais sans s'y...